Citius Pharmaceuticals CTXR Estimates

NASDAQ CTXR
$0.59 +0.00 (+0.57%)
At close: Sep 10, 2026 · 4:00 PM EDT
Analyst Estimates

Citius Pharmaceuticals, Inc. Revenue Estimates

Periods 25
Next Period Q4 24
Consensus 0.00

Analysts expect Citius Pharmaceuticals, Inc. to report revenue of 0.00 for Q4 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 26, came in at 1.49 M, a 72.0% miss against the 5.31 M consensus.

Metric Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.000.000.003.94 M3.94 M1.67 M1.49 M-------
High Estimate 0.000.000.002.25 M0.0018.76 M11.46 M5.52 M3.27 M4.25 M5.02 M6.11 M6.58 M11.40 M12.10 M
Low Estimate 0.000.000.001.85 M0.0015.83 M10.08 M5.11 M2.81 M3.91 M4.23 M5.21 M5.58 M9.79 M10.27 M
Consensus Estimate 0.000.000.002.05 M0.0017.30 M10.77 M5.31 M3.04 M4.08 M4.63 M5.66 M6.08 M10.59 M11.18 M
Analyst Estimates

Citius Pharmaceuticals, Inc. Earnings Per Share (EPS) Estimates

Periods 25
Next Period Q4 26
Consensus -0.38

Analysts expect Citius Pharmaceuticals, Inc. to report earnings per share of -0.38 for Q4 26, against a range of -0.41 to -0.35. The most recent reported quarter, Q3 26, came in at -0.34 , in line with the -0.34 consensus.

Metric Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -1.72-1.30-1.27-0.80-0.01-0.38-0.95-0.34--------
High Estimate -1.40-1.22-0.33-0.48-0.370.43-0.25-0.33-0.35-0.33-0.34-0.37-0.06-0.25-0.33-0.20
Low Estimate -1.54-1.44-0.37-0.52-0.450.37-0.29-0.35-0.41-0.41-0.40-0.43-0.06-0.27-0.39-0.22
Consensus Estimate -1.47-1.33-0.35-0.50-0.410.40-0.27-0.34-0.38-0.37-0.37-0.40-0.06-0.26-0.36-0.21